Gefitinib (Iressa; AstraZeneca, London, England) has been used in the treatment of non–small cell lung cancer (NSCLC).1 The cutaneous toxic effects associated with epidermal growth factor receptor (EGFR) inhibitors are follicular eruption, paronychia, and xerosis.2-4 Herein, we describe 3 patients with reticular erythematous eruptions on the lower extremities associated with gefitinib.
Sheen Y, Hsiao C, Chu C. Severe Purpuric Xerotic Dermatitis Associated With Gefitinib Therapy. Arch Dermatol. 2008;144(2):269–270. doi:10.1001/archdermatol.2007.53
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: